Skip to main content
SonoNeu logo

SonoNeu

Palo Alto, California, United StatesSee on the map

SonoNeu is a General Inception spinout developing sonogenetics as a novel therapeutic modality. Its platform uses ultrasound to control engineered ion channels, aiming to enable non-invasive treatments.

Open roles
1
Raised
$5.2M
Investor
1
Employees
2–10

reccy insights

Recent highlights

SonoNeu’s clearest reported milestone is a $5.2 million grant announced on Apr 7, 2026, with the Advanced Research Projects Agency for Health identified as the lead funder. The funding supports the company’s work on sonogenetics, an approach that uses focused ultrasound to control engineered cells. SonoNeu describes its platform as drug-free and non-invasive, with potential applications that include peripheral and diabetic neuropathy; these are areas of intended development, not evidence of approved treatments or demonstrated clinical outcomes. The company’s founding team includes Venkat Reddy and Sreekanth Chalasani. The available employee range is 2–10, indicating a small team, but there is no specific hiring announcement or reported workforce change to highlight. Overall, the grant is a notable financing and research milestone, while public details on execution and clinical progress remain limited.

Written by reccy's AI from company sites, press and funding records · updated Nov 2026

Open roles1

What makes SonoNeu distinct

  1. 01Develops sonogenetics as a potential therapeutic modality.
  2. 02Uses focused ultrasound to control engineered cells.
  3. 03Targets engineered ion channels as part of its platform approach.
  4. 04Aims to enable non-invasive, drug-free therapeutic interventions.

Technology & products

  • SonoNeu sonogenetics platform

    A non-invasive platform using focused ultrasound to control engineered cells and ion channels, with potential therapeutic applications including peripheral and diabetic neuropathy.

  • Sonogenetics platform using ultrasound to control engineered ion channels.

Research roots1

Labs and research groups this company came from or works with.

Academic data: Carter Sciences

Funding

$5.2M disclosed
Latest valuation Up to $41.3M1 investor

Investors1

About SonoNeu

Products
SonoNeu sonogenetics platform
Leadership
Venkat ReddySreekanth Chalasani
Focus areas
Biotechnology, therapeutics, sonogenetics, focused ultrasound, engineered ion channels, neuropathy
Headquarters
Palo Alto, California, United States
Employees
2–10